Halda Therapeutics
Chris Forbes has a diverse work experience spanning various roles and companies. In 2002, Chris started as a Research Associate at Bayer Pharmaceuticals and worked there until 2007. From 2007-2008, Chris worked as a Research Associate at RainDance Technologies and as an Internal Sales Associate at MetLife Investors. In 2008, Chris worked as a Support Specialist at Warner Instruments and as a Research Scientist at BioRelix. From 2012-2013, Chris served as a Senior Research Associate at Roche - 454. From 2013-2017, Chris worked at Alexion Pharmaceuticals, starting as a Research Associate III, then progressing to Research Associate IV and finally becoming a Scientist I. From 2017-2019, Chris worked as a Business Analyst at Core Informatics. Since 2019, Chris has been working at Halda Therapeutics, initially as a Research Investigator and then progressing to Principal Scientist, Associate Director, and currently serving as the Director of Biology, Profiling Lead.
Chris Forbes completed their education in a progressive manner. Starting in 1988, they attended Windsor Locks, although no degree or field of study is mentioned. From 1993 to 1996, they pursued a Bachelor's degree in Biology from the University of Connecticut. This was followed by a Master's degree in Health Physics from Texas A&M University, which they obtained between 1996 and 1999. Finally, Chris completed their education with a Master's degree in Pharmacology from Yale University, where they studied from 1999 to 2002.
This person is not in any offices
Halda Therapeutics
1 followers
Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines. Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.